Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal ...(theprostate. SARMs provide the opportuni...),Health

Date:6/9/2008

the prostate. SARMs provide the opportunity to design tissue-selective, orally delivered anabolic therapies for bone loss and/or muscle wasting caused by aging, burns and trauma, cancer, chronic kidney disease, end-stage renal disease, chronic obstructive pulmonary disease (COPD), and other diseases.

About Sarcopenia

About 17% of men and 24% of women under the age of 70 suffer from age-related muscle wasting, or sarcopenia. The degenerative loss of skeletal muscle mass and strength contributes to frailty, immobility, and the loss of independence in older adults, with prevalence rising to more than 50% in men and women over 80 years of age. An estimated nine million Americans over the age of 65 suffer from sarcopenia, and there are currently no FDA-approved treatment options available. This deterioration of skeletal strength can also exacerbate other age-related conditions such as osteoarthritis and osteoporosis. Additional chronic diseases that involve loss of muscle strength with a significant impact on quality of life include cancer cachexia, chronic obstructive pulmonary disease (COPD), and chronic renal disease.

ABOUT RADIUS (http://www.radiuspharm.com)

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $91.5 million in private equity financing since its establishment in 2003 and is based in Cambridge, Massachusetts.

Contact:

Nick Harvey

Chief Financial Officer

(617) 551-4704

'/>"/>

SOURCE Radius Health Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2
Related medicine technology :

1. Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
2. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
6. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
7. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
10. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
11. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer